Isigulana sase-Australia Sifumana Impendulo Emangalisayo Kwangoko nge-BIOOCUS Medical Group's Dual CD19/CD20 CAR-T Therapy ye-DLBCL ephinde yabuyela kwi-DLBCL
URodney Charles Monger, indoda eneminyaka engama-68 ubudala evela e-Australia, ufunyaniswe enesifo esibizwa ngokuba yi-diffuse large I-B-Cell Lymphoma (DLBCL) kwiminyaka emithathu eyadlulayo. Efuna unyango oluphambili, wabhenela kwi-BIOOCUS Medical Group ngo-Agasti 2025. I-biopsy ye-lymph node yomlomo wesibeleko yaqinisekisa ukuba kukho i-B-cell lymphoma ehlaselayo evela kwiziko le-germinal. I-Immunohistochemistry yayine-CD20, CD19, kunye ne-CD10, kunye nokubonakaliswa okuphezulu kwe-Bcl-6, Bcl-2 (70%+), kunye ne-c-MYC (60%+). Uvavanyo lwe-genetic lubonise ukulungelelaniswa kwe-BCL2 yi-FISH kunye nokuguqulwa kwe-EZH2, KMT2D, TNFRSF14, NRAS, kunye ne-TPMT genes—iimpawu ezicacileyo zeprofayili enobundlongondlongo, enomngcipheko ophezulu.
Emva kokufumana i-pola edityaniswe ne-BTK inhibitor kunye ne-lenalidomide, kulandele i-FC lymphodepletion chemotherapy, isifo sikaMnu. Monger sahlala singanyangeki. Iqela le-BIOOCUS Medical Group licebise unyango lwabo olutsha lwe-CD19/CD20 CAR-T cell olujolise kwi-dual-targeting.
Ngomhla wesi-8 kuSeptemba, ngo-2025, uMnu. Monger wafumana utyando lweeseli ze-autologous CD19/CD20 CAR-T. Okumangalisayo kukuba, akazange abe namava e-cytokine release syndrome (CRS) kwaye akazange abe namava e-immune effect cell-associated neurotoxicity syndrome (ICANS), nto leyo eyabangela ukuba ahambe kakuhle emva kotyando olwamgcina ezinzile kwaye enethemba ukususela ngomhla wokuqala.
Ukuhlolwa kwegazi okujikeleze igazi kubonise ukwanda okumangalisayo kweeseli ze-CAR-T, okuqinisekisa ukufakelwa kunye nokwanda okugqwesileyo. Ngomhla wesi-4 emva kokufakwa, iiseli ze-CAR19+ zaziyi-0.50% yeeseli ze-CD3+ T (ixabiso elipheleleyo yi-6.04 × 10⁷/L) kunye neeseli ze-CAR20+ ziyi-0.41% (4.96 × 10⁷/L). Ngomhla wesi-7, i-CAR19+ inyuke yaya kwi-1.68% (1.40 × 10⁷/L) kunye ne-CAR20+ yaya kwi-1.63% (1.36 × 10⁷/L). Ngomhla we-10, i-CAR19+ ifikelele kwi-31.43% yeeseli ze-CD3+ T (ixabiso elipheleleyo yi-3.13 × 10⁸/L) kwaye i-CAR20+ yafikelela kwi-32.74% (ixabiso elipheleleyo yi-3.26 × 10⁸/L). I-Flow cytometry ibonise ngakumbi ukusasazwa okulinganayo kwii-CD4+ kunye ne-CD8+ subsets kunye nokubonakaliswa okunamandla kwe-CAR kabini, okubonisa amandla onyango okukhuthaza ukuqina okuqinileyo kwe-in-vivo kunye nokwanda.
Kwingxelo yokugqibela (usuku lwe-10), uMnu. Monger uyaqhubeka nokusebenza kakuhle ngokwezonyango. Usebenzisa amayeza omlomo alungiselelwe wena aquka i-acyclovir, i-compound sulfamethoxazole, i-orelabrutinib, i-lenalidomide, kunye neearhente ezixhasayo, kunye nokujonga rhoqo inani legazi, ukusebenza kwesibindi kunye nezintso, kunye neempawu zokuvuvukala.
Iqela le-BIOOCUS Medical Group linike inkxaso epheleleyo, egxile kwizigulane kulo lonke ixesha, kuquka indawo yokuhlala ekhululekileyo, ukutya okunesondlo, uncedo lokuhamba, kunye neengcebiso zengqondo kuMnu. Monger kunye nosapho lwakhe. Le ndlela ipheleleyo yamvumela ukuba agxile ngokupheleleyo ekuchacheni.
Ityala likaMnu. Monger libonisa amandla okuguqula indlela yonyango lwe-BIOOCUS Medical Group olusebenzisa i-CD19/CD20 CAR-T ezimbini kwizigulane ezine-DLBCL ephinde yabuyela kwisimo sayo/engasasebenziyo. Ukwanda ngokukhawuleza nangokuqinileyo kweeseli ze-CAR-T ngaphandle kwetyhefu eqatha kugxininisa iprofayili yokhuseleko olufanelekileyo lwemveliso kunye nomsebenzi onamandla wokulwa nethumba—nangona kwisigulana esikhulileyo esineempawu zeemolekyuli ezinobungozi obukhulu.